New York, May 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031 ...

Researchers found that adding a newly developed modified sugar, BNAP-AEO, to gapmer antisense oligonucleotides (ASOs) increased their affinity for target RNAs, thus significantly enhancing their ...

In the course of our study for the role of cyclic AMP response element-binding protein (CREB), a cyclic AMP-dependent transcription factor1 2 3 being involved in cell survival control in certain ...

Microangiopathy is a disorder of small blood vessels. Diabetic microangiopathy, or retinopathy, is a predominant abnormality of retinal vasculature and is the leading cause of blindness among ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

Researchers have devised a molecular structural modification that boosts the efficacy of antisense oligonucleotide-based drugs by replacing the RNA strand of a heteroduplex oligonucleotide with DNA.

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

Forty patients were enrolled and treated (14 patients in phase I and 26 patients in phase II). Dose-limiting reactions in phase I included hypotension and fever, and the MTD for phase II dosing was ...

(MENAFN- Navistrat Analytics) July 09, 2025 - The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense Oligonucleotide (ASO) therapeutics market.

Patrick Lewis receives funding from the Medical Research Council, Biotechnology and Biological Sciences Research Council, National Institutes of Health and Parkinson's UK. He sits on the Scientific ...

A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye, ...

Researchers from Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, USA, report a modification wherein replacing the RNA strand of a heteroduplex oligonucleotide with DNA may ...